Fig. 8
Effectiveness of sorafenib-loaded MOFs (SOR-MIL-53) in enhancing anticancer activity against hepatocellular carcinoma (HepG2) and colorectal cancer (HCT-116) cell lines, with reduced toxicity observed in normal fibroblast cells (HFb-4).
Fig. 8 | Scientific Reports
